In the indications of O medicine and K medicine folding, why does H medicine stand out? What is its hardcore
Time of Update: 2022-09-20
It is worth noting that a phase III clinical trial of slullizumab (H drug) independently developed by the domestic pharmaceutical company Henlius was orally reported at the ASCO annual meeting, which is also the first time that China's local PD-1 has appeared in the field of ASCO first-line lung cancer in the form of oral reports.
An article to sort out the mechanism of action of hydroxychloroquine (HCQ) and chloroquine (CQ
Time of Update: 2022-08-16
Affecting multiple cellular pathways through different mechanisms, CQ and HCQ inhibit multiple endolysosomal functions, including autophagy, as well as endosomal Toll-like receptor activation and calcium signaling , as the therapeutic use of HCQ is expanding to treat both malaria and RAD.
It is difficult to develop new drugs, and a large number of drugs end in clinical failure
Time of Update: 2022-05-10
Some industry insiders who have been engaged in new drug research and development for many years said that there are five main reasons for the failure of the management of new drug research and development projects they participated in, including project approval mistakes, lack of project-matching stakeholders, uncertainty in technical risks, and late R&D application progress.
Application of Silicone Pressure Sensitive Adhesive in Consumer Electronics Industry
Time of Update: 2021-12-02
With its advantages in high and low temperature resistance, weather resistance, exhaust gas, and light transmittance, silicone pressure-sensitive adhesives have become the best choice in the field of electronic protective films .
[Live Preview] Diagnosis and Treatment of Youth Stroke
Time of Update: 2021-10-20
Common causes of stroke in youthStroke2.
Clinical features and diagnosis of stroke in young peoplediagnosis3.
Treatment of youth stroke Live time: 19:00, October 15, 2021Live time: Guest introductionGuest Introduction Guest IntroductionWang Xun, female, doctor, postdoctoral, chief physician .
Xu Huaqiang's research group from Shanghai Institute of Medicine reveals the selective action mechanism of anti-migraine drugs
Time of Update: 2021-08-08
Recently, Xu Huaqiang's research group at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences used cryo-electron microscopy to analyze the complex structure of 5-HT1F receptor binding G protein and the anti-migraine drug lamitetan for the first time, revealing the selectivity of lamitetan Bind to the structural basis of 5-HT1F receptor .
Cell Journal: The molecular mechanism of arginine methyltransferase Prmt7 in precise regulation of antiviral innate immunity
Time of Update: 2021-08-08
Recently, Xiao Wuhan's team from the Institute of Hydrobiology, Chinese Academy of Sciences revealed the molecular mechanism of the protein arginine methyltransferase Prmt7 that precisely regulates the antiviral innate immune response .
Express more than 2 billion U.S. dollars to help develop anti-TIGIT antibodies, GSK adds a new generation of cancer immunotherapy
Time of Update: 2021-06-22
▲ GSK's R&D layout for the CD226 signaling pathway (picture source: reference ) EOS-448 developed by iTeos is an anti-TIGIT monoclonal antibody with multiple mechanisms of action .
JAMA: The influence of traditional synthetic anti-rheumatic drugs on the risk of relapse
Time of Update: 2021-05-20
Studies believe that for patients with rheumatoid arthritis who have received traditional synthetic anti-rheumatic drugs to improve their condition, the risk of recurrence increases after the drug dose is reduced by half during the maintenance treatment period.
Eur Spine J: Efficacy of golimumab in the treatment of ankylosing spondylitis-a systematic review and meta-analysis
Time of Update: 2021-05-20
gov/32447529/" target="_blank" rel="noopener">Patients with ankylosing spondylitis treatment by golimumab: a systematic review and meta-analysis .
gov/32447529/" target="_blank" rel="noopener">Patients with ankylosing spondylitis treatment by golimumab: a systematic review and meta-analysis in this message
WHO: The number of new confirmed cases of new crowns in the world last week hit a record
Time of Update: 2021-04-22
This is the eighth consecutive week of new confirmed cases of new crowns in the world; the number of new crown deaths worldwide has also increased for 5 consecutive weeks.
Unrasing the Code of Aging 2 studies in the same period in the journal Nature put forward new ideas for anti-aging therapy
Time of Update: 2021-01-19
The niacinamide adenine dinucleotide, referred to simply as NAD, is a key metabolite of cell energy metabolism and a star in the field of anti-aging in recent years. studies have shown that, as we a
Two Cell papers reveal that powerful human-medium antibodies are expected to fight attacks from eastern horse encephalitis, Hendra and Nipah viruses
Time of Update: 2020-12-28
results were published in the December 10, 2020 issue of cell, under the title "Potent Henipavirus Neutralization by Antibodies Recognizing Diverse Sites on Hendra and Nipah Virus Receptor Protein Binding." from Cell, 2020, doi:10.1016/j.cell.2020.11.023.
Towards water-based marine coatings
Time of Update: 2020-12-06
At present, China continues to introduce emission standards, levy VOC sewage charges and give treatment subsidies, some urban sewage charges have been higher than or close to the cost of pollution control, in addition to VOC prevention and control countries are strongly supporting the development of aerospace, ship docks, high-end cars, bridge steel structure, marine, wind power generation and other industries in urgent need of high-grade special coatings, improve product quality, replace imports.
Cinda BioCD47/PD-L1 B2specific Antibody Phase I Clinical Study completed the first patient administration in China
Time of Update: 2020-08-05
Cinda Biopharmaceuticals has just announced that its potential lying phase I clinical study of anti-CD47/PD-L1 bispecific antibodies (research code: IBI322) has completed the first patient administration in China.
, the development of anti-CD47/PD-L1 bispecific antibodies will provide patients with a new, comprehensive, effective and cost-effective treatment.